Government Properties' revised business plan impacts 15 employes Theratechnologies announced its revised business plan which will focus on revenue growth from tesamorelin in the short term and expenditure control. Stimulating more potential revenues from tesamorelin in the short term and expenditure control.Business plan included a re-alignment of Theratechnologies' priorities in the short term has led to the suspension of most of its internal long-term R&D activities, which will impact approximately 15 employees. This will result in restructuring costs of $ 5.4M. This includes $2.5M in employee compensation, inclusive of the former CEO, and $2.9M in non-cash items such as lease and lab equipment write-offs. Most of these restructuring costs will be registered in the Q4.
News For GOV From The Last 14 Days
Check below for free stories on GOV the last two weeks.